Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Julphar
Boehringer Ingelheim
McKesson
Merck
Novartis
Queensland Health
Cerilliant
Daiichi Sankyo

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205126

« Back to Dashboard

NDA 205126 describes CARISOPRODOL, which is a drug marketed by Able, Accelrx Labs, Aurobindo Pharma, Epic Pharma Llc, Hikma Intl Pharms, Ingenus Pharms Nj, Natco Pharma Ltd, Nostrum Labs Inc, Orient Pharma Co Ltd, Oxford Pharms, Pioneer Pharms, Sandoz, Sciegen Pharms Inc, Strides Pharma, Sun Pharm Inds Ltd, Sun Pharm Industries, Vintage Pharms, Watson Labs, Watson Labs Teva, Wilshire Pharms Inc, Heritage Pharms Inc, and Novast Labs Ltd, and is included in thirty-one NDAs. It is available from fifty-three suppliers. Additional details are available on the CARISOPRODOL profile page.

The generic ingredient in CARISOPRODOL is aspirin; carisoprodol; codeine phosphate. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; carisoprodol; codeine phosphate profile page.

Summary for 205126

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Skeletal Muscle Relaxants
Formulation / Manufacturing:see details

Pharmacology for NDA: 205126

Suppliers and Packaging for NDA: 205126

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CARISOPRODOL carisoprodol TABLET;ORAL 205126 ANDA Wilshire Pharmaceuticals, Inc. 52536-682 52536-682-10 100 TABLET in 1 BOTTLE (52536-682-10)
CARISOPRODOL carisoprodol TABLET;ORAL 205126 ANDA Wilshire Pharmaceuticals, Inc. 52536-688 52536-688-10 100 TABLET in 1 BOTTLE (52536-688-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:Jul 8, 2015TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength350MG
Approval Date:Jul 8, 2015TE:AARLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
McKinsey
Chubb
US Department of Justice
Harvard Business School
QuintilesIMS
US Army
Queensland Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot